Acute Lymphoblastic Leukemia News and Research

RSS

Acute lymphoblastic leukemia (ALL) is a cancer of the white blood cells, the cells in the body that normally fight infections. There are two main types of white blood cells-lymphoid cells and myeloid cells. ALL affects lymphoid cells.

The Josep Carreras Leukaemia Research Institute joins Cancer Proteome Project

The Josep Carreras Institute becomes part of the Cancer Proteome project, an international initiative for the study of malignant tumors.

6 May 2022

Novel method could bring life-saving benefits of CAR T-cell therapy to patients with acute myeloid leukemia

Massachusetts General Hospital researchers have developed a novel treatment strategy that has the potential to bring the life-saving benefits of chimeric antigen receptor T-cell therapy (CAR T) to patients with acute myeloid leukemia (AML) the most common form of leukemia in adults.

28 Apr 2022

Researchers identify certain gene regulation signatures in CAR T-resistant leukemia patients

Acute lymphoblastic leukemia (ALL) cells from patients whose cancers did not respond to CD19-targeted CAR T therapy had gene regulation signatures that could potentially facilitate treatment resistance, according to results presented at the AACR Annual Meeting 2022, held April 8-13.

13 Apr 2022

Study finds higher risk of all-cause mortality among pediatric cancer patients in LMICs during the pandemic

During the first nine months of the COVID-19 pandemic, pediatric cancer patients from lower- and middle-income countries faced a higher risk of all-cause mortality than those in high-income countries, according to data presented at the AACR Annual Meeting 2022, held April 8-13.

11 Apr 2022

Colonization of subventricular neurogenic niche by leukemia cells prevents the formation of new neurons

The subventricular neurogenic niche is a region of the brain where tumor cells can hide from chemotherapy treatment to reappear later, causing relapses in patients with childhood acute lymphoblastic leukemia (ALL), and preventing the formation of new neurons, as demonstrated by research led by Universidad Complutense de Madrid (UCM).

30 Mar 2022

Penn researchers generate functional CAR T cells with enhanced anti-tumor potency in 24 hours

A new approach from Penn Medicine researchers could cut the time it takes to alter patients' immune cells for infusion back into the body to find and attack cancer.

29 Mar 2022

Study raises hopes for effective treatment of infant B acute lymphoblastic leukemia

New research has begun to unravel the mystery of why a particular form of leukemia in infants has defied efforts to improve outcomes, despite significant improvements in treating older children.

14 Mar 2022

Research reveals a possible strategy to prevent B-cell acute lymphoblastic leukemia

Short-term treatment with the drug ruxolitinib prevents B-cell acute lymphoblastic leukemia (B-ALL) in mice that have a genetic predisposition to the disease.

8 Feb 2022

New personalized test to detect leukemia relapse sooner and avoid false negative results

Researchers have developed a new protocol for monitoring acute lymphoblastic leukemia (ALL), the most common cancer in children, to inform more effective treatment strategies and detect disease recurrence.

7 Feb 2022

Study identifies a genetic mutation linked to high risk of lethal childhood leukemia

A genetic variant changing just one base pair of nucleotides greatly increases risk of a high-risk subtype of childhood acute lymphoblastic leukemia (ALL), according to a Northwestern Medicine study published in Nature Genetics.

3 Feb 2022

New approach to CAR T-cell therapy for B-cell cancers triples the targeted antigens on cancer cells

Researchers at University Hospitals Seidman Cancer Center and Case Western Reserve University have developed a novel approach to chimeric antigen receptor (CAR) T-cell therapy for B-cell cancers that triples the targeted antigens on cancer cells – a "back up" approach that promises to greatly reduce the potential for antigen escape currently found in CAR T therapies that solely target CD19.

2 Feb 2022

Overall survival rate has nearly doubled for Ph+ ALL patients after hematopoietic stem cell transplant

For patients with acute lymphoblastic leukemia (ALL) carrying the Philadelphia chromosome and whose disease relapsed after allogeneic hematopoietic stem cell transplantation (HCT), the two-year overall survival rate has nearly doubled from the period between 2000 and 2004 to the period between 2015 and 2019.

13 Jan 2022

Amino acid valine plays a key role in the growth of T cell acute lymphoblastic leukemia

A molecular building block of many animal proteins, the amino acid valine, plays a key role in cancerous growth seen in T cell acute lymphoblastic leukemia, a new study shows.

22 Dec 2021

Scientists develop new immunotherapy for cancer based on transplant rejection mechanism

A team of scientists at the University of Oslo, Oslo University Hospital Radiumhospitalet and Karolinska Institutet, led by Professor Johanna Olweus, has developed a new type of immunotherapy for cancer.

18 Dec 2021

Study reveals molecular players involved in the onset of leukemia

A new study led by João T. Barata from Instituto de Medicina Molecular João Lobo Antunes (iMM, Portugal), and J. Andrés Yunes from Centro Infantil Boldrini (Brazil), published now in the scientific journal Nature Communications, shows that changes in a protein called IL-7R are sufficient to initiate a type of leukemia.

14 Dec 2021

Researchers uncover a key role for SIRT1 enzyme in T-cell acute lymphoblastic leukemia

T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive type of leukemia. Despite advances in treatments, patients have an extremely poor prognosis, highlighting the need to explore the genetic components that lead to the formation of T-ALL, as well as the need to discover new targeted therapeutic approaches and treatment resistance.

14 Dec 2021

Drug combination without chemotherapy can be effective in treating older patients with Ph+ ALL

The combination of dasatinib, blinatumomab, and prednisone can be effective in treating older patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) who are not good candidates for intensive chemotherapy treatment.

13 Dec 2021

New genetic technology for gene expression analysis of cancer cells

In this interview, News-Medical speaks to Dr. Rong Lu about her recent research into the development of a new genetic technology for gene expression analysis of cancer cells.

3 Dec 2021

DNA sequencing of residual disease accurately identifies leukemia patients who would relapse

In pediatric and young adult patients with acute lymphoblastic leukemia (ALL) treated with tisagenlecleucel (Kymriah), DNA sequencing-based detection of residual disease between three and 12 months accurately identified all patients who would eventually relapse, while other methods were less predictive.

1 Dec 2021

CIRM awards $4.1 million to advance CAR T-cell therapy from the lab to clinic

On November 23, 2021, the California Institute for Regenerative Medicine (CIRM) governing board approved a $4.1 million grant to enable University of California San Diego School of Medicine researchers to advance a new chimeric antigen receptor (CAR) T-cell therapy from the laboratory into the clinic.

24 Nov 2021